Seladelpar, also known by its brand name Livdelzi, is approved by the U.S. Food and Drug Administration (FDA) for treating primary biliary cholangitis (PBC) in adults. It is prescribed in combination with ursodeoxycholic acid (UDCA) for those who do not respond adequately to UDCA alone or as a monotherapy for those who Show Full Answer

Seladelpar, also known by its brand name Livdelzi, is approved by the U.S. Food and Drug Administration (FDA) for treating primary biliary cholangitis (PBC) in adults. It is prescribed in combination with ursodeoxycholic acid (UDCA) for those who do not respond adequately to UDCA alone or as a monotherapy for those who cannot tolerate UDCA.

Key Points About Seladelpar (Livdelzi):
- Mechanism: It is a peroxisome proliferator-activated receptor (PPAR)-delta agonist, believed to work by reducing alkaline phosphatase (ALP) levels.
- Administration: Taken orally as a capsule once daily, with or without food.
- Common Side Effects: Headache, abdominal pain, nausea, abdominal distension (bloating), and dizziness.
- Serious Side Effects: Fractures, liver test abnormalities, and biliary obstruction.

For more detailed experiences and discussions, you might want to visit the myPBCteam website where individuals share their experiences with treatments like Livdelzi.

 This AI-generated response comes from myPBCteam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

Livdelzi (Seladelpar) for PBC | myPBCteam

Iqirvo (Elafibranor) for PBC | myPBCteam